Lumenis

Lumenis Ltd. is an Israeli company specializing in the development, production and implementation of lasers and laser systems, minimally invasive clinical solutions for ophthalmic, surgical, dental, veterinary industries and the "beauty industry."

The headquarters is located in the industrial zone of Yokneam Industrial Park in Israel. Branches in the United States are located in Santa Clara (California) and Salt Lake City (Utah); branches are also available in the UK, France, Italy, Germany, Holland, Japan and Hong Kong.

Lumenis is a portfolio company of XIO Group, an international specialist in the field of alternative investments with its head office in London.

Activities

• Surgical lasers - for the treatment of diseases in the field of gastroenterology, gynecology, orthopedics, for operations on the larynx, ears, nose, legs, lungs, genitourinary system, etc.
• Ophthalmological lasers - for operations on the retina, for glaucoma and general ophthalmology.
• Dental lasers.
• Lasers for the "beauty industry" - for tooth whitening, depilation, "removal" of veins, tattoos and pigment spots, "cleaning" of skin, etc.
• Lasers for various veterinary purposes.

Business in Russia

In Russia for 2017, Premium Aesthetics LLC is the exclusive distributor of Lumenis.

History

2021: Boston Scientific buys Lumenis surgical business for $1.1 billion

In early March 2021, Boston Scientific entered into a final agreement to acquire the Lumenis surgical business, which develops and commercializes energy devices, for $1.1 billion.

According to the press release, the transaction includes an advance payment of $1.07 billion, taking into account adjustments at the close of the transaction. The parent company Baring Private Equity Asia (BPEA) is planned to retain ownership of Lumenis's aesthetic medicine and ophthalmology business, while Boston Scientific will take over the surgical business, which is expected to generate revenue of about $200 million in 2021. The company expects the deal to be completed in the second half of 2021.

The surgical portfolio of the Israeli company Lumenis includes laser systems and accessories for urological and otolaryngological procedures, including the patented Moses technology for the treatment of patients with kidney stones. The Moses system provides laser lithotripsy using a urethroscope to determine the location of the stone.

Boston Scientific acquired Lumenis surgical business for $1.1 billion

Moses laser technology, combined with our one-time digital flexible urethroscope LithoVue and a comprehensive portfolio of solutions for the treatment of kidney stones, will fully implement our strategy, "explained Meghan Scanlon, senior vice president of pelvic urology and health at Boston Scientific. - This acquisition will allow us to expand our market share in Europe and Asia and will ultimately help a large number of patients around the world.

By early March 2021, Boston Scientific has partnered with Lumenis for more than 20 years and has been selling Lumenis's urological laser portfolio in the United States and Japan under a distribution agreement. The new deal will allow Boston Scientific to enter the market in fast-growing regions such as China.^[1]

2019: Acquisition by Baring Private Equity Asia

On November 21, 2019, it became known that an investment holding from Hong Kong Baring Private Equity Asia (BEPA) announced a deal to acquire the Israeli cosmetics company Lumenis from the Chinese company XIO.

According to The Times Of Israel, the deal is over 1 billion. dollars It is planned to complete the transaction in early 2020, subject to approval from supervisory authorities, reports. TASS

As of November 2019, Lumenis operates in 100 countries and has a staff of almost 1,500 employees. Asia Pacific is the company's largest market. It is equally widely represented in North America and EMEA.^[2]

During its existence, the company has established itself as a global manufacturer of innovative cosmetic and medical devices, specializing in cosmetic care for the face and body, the treatment of skin and eye diseases, as well as developing specialized medical devices for the treatment of problems in the field of urology.

As noted, Lumenis led the development and was the first to use laser technology, intense pulsed light and radio frequencies in the treatment. In particular, the company developed the world's first surgical laser for the destruction of kidney stones and the treatment of urolithiasis.^[3]

2015: Purchase by Chinese holding company XIO

In 2015, the company was bought for half a billion dollars by the Chinese investment holding XIO, which excluded the shares of the Israeli company from the largest technology exchange Nasdaq.

2006: LM Partners L.P. and Ofer Hi-Tech Group buy back 75% stake in Lumenis

In 2006, in exchange for an investment of $120 million, two private Israeli firms (LM Partners L.P. and Ofer Hi-Tech Group) sold a 75% stake in Lumenis.

2004: Expulsion from NASDAQ exchange for problems in financial statements

Due to problems with financial reporting, the company's shares were removed from the NASDAQ stock exchange in 2004.

2001: Formation of Lumenis

Lumenis was formed in 2001 after the acquisition by the Israeli company ESC Medical Systems of the American Coherent Medical Group for $203 million.

1973: Foundation of the company

Lumenis was founded in 1973.

Notes